Psychedelics As Therapeutics – What Developers Need To Know

By Yolande Haydon, MS, PMP

Psychedelic therapeutics have garnered significant attention from both investors and drug developers. However, these stakeholders face a delicate balancing act, weighing the opportunities against the distinctive challenges associated with developing these therapies.

Yolande Haydon recently participated in the 3rd annual Psychedelic Therapeutic and Drug Development Conference and noted that the event was a treasure trove of insights, featuring researchers, investors, sponsors, and economists, each offering their unique yet complementary perspectives on the potential of psychedelics as therapeutic agents.

Upon returning home, Haydon had the opportunity to contemplate the various presentations, posters, and engaging lunchtime discussions, leading to the identification of key takeaways. These insights aim to provide valuable guidance for drug developers and others intrigued by this dynamic and promising field.